Elutia Inc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ELUT research report →
Range $5 – $10.5
Price Chart
About the company
Elutia Inc. , a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular.
- CEO
- C. Randal Mills
- IPO
- 2020
- Employees
- 26
- HQ
- Gaithersburg, MD, US
Get TickerSpark's AI analysis on ELUT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $39.86M
- P/E
- 0.63
- PEG
- 0.00
- P/S
- 3.61
- P/B
- 2.34
- EV/EBITDA
- -0.49
- Div Yield
- 0.00%
- Gross Margin
- 58.95%
- Op Margin
- -262.20%
- Net Margin
- 546.70%
- ROE
- 267.71%
- ROIC
- -81.11%
Latest fiscal year · YoY change
- Revenue
- $12.29M-49.6%
- Gross Profit
- $6.60M-38.4%
- Op Income
- $-26,911,000
- Net Income
- $53.38M+198.9%
- EPS
- $0.94+150.5%
- OCF Growth
- -97.8%
- FCF Growth
- -100.3%
- 52W High
- $1.39
- 52W Low
- $0.50
- 50D MA
- $0.82
- 200D MA
- $0.97
- Beta
- 0.92
- RSI (14)
- 57
- Avg Volume
- 185.17K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Elutia said Q3 results reflected higher revenue and margins in the cardiovascular business, while the bigger story was progress toward submitting NXT-41X and funding the launch without an equity raise.· November 5, 2026
- NXT-41X’s GLP rabbit study met prespecified endpoints, and management said the FDA submission is planned for this quarter.
- Management said NXT-41X clearance could come in the second quarter of 2027, followed by a soft launch in the second half of 2027 and full launch in 2028.
- The company raised $26 million in non-dilutive funding over 51 days through a loan, asset sale proceeds, and release of a holdback.
- Cardiovascular revenue grew 20% year over year in Q3, and management is still pursuing a sale but said it will not rush into a weak deal.
- Management said the automated coating system is built for at least $300 million of revenue capacity at launch and gross margin above 80% at scale.
For continuing operations, Q3 net sales were $1.1 million, up 20% from $0.9 million a year earlier. GAAP gross margin was 61.7% versus 52.8%, and adjusted gross margin was 85.5% versus 81.3%. Total operating expenses were $7.6 million versus $6.4 million, loss from operations was $6.9 million versus $5.9 million, net loss from continuing operations was $6.5 million versus $1.0 million, and adjusted EBITDA was a loss of $5.6 million versus a loss of $3.4 million. The company ended the quarter with $29.1 million in cash and cash equivalents, not including the $8 million Boston Scientific holdback received on October 1. For the cardiovascular business specifically, Q3 revenue grew 20% year over year to $1.1 million, and adjusted gross margin was 85%. Forward-looking, management expects an FDA clearance decision on NXT-41 in the current quarter, plans to submit NXT-41X this quarter, anticipates an FDA decision in Q2 2027, a soft launch in the second half of 2027, and a full commercial launch in 2028.
Randy Mills framed the quarter around an obvious unmet need in surgical infection prevention, arguing that surgeons are talking about infection but the market still offers no commercial solution. He said NXT-41X is designed to address that gap, with GLP data completed, surgeon feedback positive, and manufacturing ready for commercial production. His tone was highly confident and energetic, but he also emphasized the complexity of the program and the long regulatory path ahead.
Matt Ferguson focused on financing, saying Elutia added $26 million without an equity offering and that this should fund the company through anticipated NXT-41X clearance and the first year of launch. He broke that down into a $15 million Avenue Capital loan facility, $8 million from the SimpliDerm sale, and the $8 million Boston Scientific holdback, plus possible additional capital from the second loan tranche, SimpliDerm milestones, and a cardiovascular transaction. On the P&L, he cited Q3 continuing-ops revenue of $1.1 million, GAAP gross margin of 61.7%, adjusted gross margin of 85.5%, and year-over-year increases in operating expenses tied mainly to $1.9 million more R&D on NXT-41 and NXT-41X. He also said the company ended with $29.1 million in cash and expects a relatively small commercial organization and a not-materially-higher burn rate as launch approaches.
The main analyst questions were about barriers to entry, launch staffing, OpEx, and what remains before NXT-41X submission. Management said the moat is a combination of IP and regulatory complexity, noting both patents/trade secrets and the difficulty of engineering a uniformly drug-eluting biological matrix that surgeons will accept. On commercialization, Randy said the plan is to cover the top 16 U.S. territories by the end of 2027 using mostly direct reps, with hiring to ramp later rather than too early; Matt added that the company expects a rapid launch with a relatively small sales force. On timing, management said the heavy testing is done, the product is on stability testing, and the submission package is being assembled, with no major studies still outstanding.
The call presented a clear, differentiated product story: management believes NXT-41X addresses a large, unsolved infection problem that surgeons care about but the industry has not addressed. Bullish points include completed GLP endpoints, positive surgeon feedback, an FDA filing planned for this quarter, and a manufacturing setup that management says can support at least $300 million in revenue capacity at launch with gross margin above 80% at scale.
The biggest risks are regulatory timing and execution: management’s launch plan depends on FDA review, and they acknowledged the timeline is only an estimate with room for delays. The company is still losing money, R&D spend is increasing, and the commercial buildout will require hiring and execution even if management expects a limited sales force. There is also uncertainty around the cardiovascular divestiture, which management wants but said it will only do if the price and strategic fit are right.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 79.8%
- Shares Outstanding
- 44.29M
- Float Shares
- 35.36M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 23 ETFs
Biggest fund positions in ELUT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 10, 26 | RAKIN KEVIN | other | 176,000 |
| Nov 10, 26 | NEELS GUIDO J | other | 117,000 |
| Nov 10, 26 | Colpman David | other | 117,000 |
| Nov 10, 26 | Makes Brigid | other | 117,000 |
| Nov 10, 26 | Williams Michelle LeRoux | other | 446,000 |
| Nov 10, 26 | Ferguson Matthew | other | 446,000 |
| Nov 10, 26 | Mills C Randal | other | 895,000 |
| Sep 10, 26 | Williams Michelle LeRoux | other | 12,500 |
| Sep 10, 26 | Williams Michelle LeRoux | other | 4,269 |
| Sep 10, 26 | Williams Michelle LeRoux | other | 12,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ELUT coverage
Recent articles, reports, and earnings notes.
No research on ELUT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ELUT report →Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 17
Elutia Inc. (ELUT) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
Elutia Reports Third Quarter 2026 Results: As Plastic Surgeons Cite Infection Risk in Every Breast Research Session During National Meeting, NXT-41x Heads to FDA This Quarter, Fully Funded Through Launch
globenewswire.com · Nov 5
Elutia to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026
globenewswire.com · Oct 22
Financial Analysis: Elutia (NASDAQ:ELUT) & QuidelOrtho (NASDAQ:QDEL)
defenseworld.net · Oct 18
Analyzing Elutia (NASDAQ:ELUT) and Edwards Lifesciences (NYSE:EW)
defenseworld.net · Oct 12
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
globenewswire.com · Oct 1
Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th
globenewswire.com · Sep 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.